| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
STAMFORD, Conn.—Today, FUJIFILM  Medical Systems U.S.A., Inc., a provider of diagnostic imaging products including digital radiography and women's health solutions, announced nine of the initial healthcare systems across the United States which have selected Fujifilm's ASPIRE Cristalle mammography system with 3D imaging or Digital Breast Tomosynthesis (DBT) option in order to improve their diagnostic imaging capabilities and patient outcomes.
 
“Every day, women turn to mammography centers to know for sure whether they are healthy, at risk, or in immediate danger,” said Rob Fabrizio, Director of Strategic Marketing, Digital Radiography and Women's Health, FUJIFILM Medical Systems U.S.A., Inc. “And every day, more radiologists turn to Fujifilm for innovative imaging and technology they can trust.”
 
The ASPIRE Cristalle with DBT combines state-of-the-art, Hexagonal Close Pattern capture technology and intelligent image processing, optimizing dose and contrast based on individual breast composition. The result is low dose and fast acquisition of exceptional images for all breast types, including implants. In addition, patients may experience a noticeable improvement in comfort during procedures with Fujifilm's flexible comfort paddle design, which provides gentle and even compression designed to adapt to patient curves.
 
According to Fujifilm’s website, “DBT acquires a series of low-dose images at different angles. The acquired images are reconstructed into a series of high-resolution slices displayed individually or dynamically in a cine mode. The reconstructed tomographic images make it easier to identify lesions which might otherwise be difficult to visualize in traditional 2D mammogram images because of the presence of overlapping breast structures. Superior diagnostic accuracy and superior (lower) recall rates for non-cancer cases are possible with ASPIRE Cristalle's DBT technology.”
 
The following health providers for women's health solutions have chosen to install the ASPIRE Cristalle mammography system: Assured Imaging LLC of Tucson, Arizona is installing 15 ASPIRE Cristalle units with DBT across the country; Franklin Hospital of Benton, Illinois will install its first unit; Little River Healthcare - King's Daughters Clinic of Temple, Texas has recently installed its first ASPIRE Cristalle unit; Morton General Hospital in Morton, Washington is planning to install its first unit; Northern Radiology Imaging, PLLC of Watertown, New York has installed its first ASPIRE unit; Samaritan Medical Center, also of Watertown, New York, has installed three units; Self Regional Healthcare of Greenwood, South Carolina is planning to install its first; Tiffany Breast Care Center in Youngstown, Ohio has installed its first ASPIRE Cristalle unit; and University Suburban Health Center of South Euclid, Ohio has also installed its first unit.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue